文献速递母胎医学

胎儿三体二次无创产前筛查:公共卫生环境下的有效性研究

Secondary non-invasive prenatal screening for fetal trisomy: an effectiveness study in a public health setting.
PubMed 文献 · BJOG · 2020-09-14

在伦敦教学医院的 NHS 常规环境下,回顾性评估 8651 例妊娠使用 SAFE 实验室无创产前检测(NIPT)进行胎儿三体二次筛查的有效性。平均周转时间 4.0 天,21 三体灵敏度 98.9%,13/18 三体灵敏度 90.4%,未出结果率 0.37%。作者认为高通量 NIPT 可有效嵌入公共卫生 NHS 环境,临床可接受的周转时间和未出结果率均在理想范围内。

要点

  • 平均周转时间 4.0 天(95%CI 4.0-4.2 天),未出结果率 0.37%(32/8651)。
  • 21 三体灵敏度 98.9%(95%CI 95.9-99.9%),13/18 三体灵敏度 90.4%(95%CI 80.0-96.8%)。
  • 孕周、双绒毛膜双胎、恶性肿瘤史及 13/18 三体妊娠影响未出结果风险,孕妇体重和低分子肝素使用不影响。

核心结论

  • 高通量 NIPT 可有效嵌入公共卫生 NHS 环境,4 天周转时间和低于 0.5% 的未出结果率在临床可接受范围内。
  • 孕周、孕妇体重、辅助生殖技术、低分子肝素使用及既往恶性肿瘤史对未出结果率无重大影响,不应构成不向女性提供 NIPT 选项的理由。

研究设计与样本

  • 回顾性队列研究,纳入 8651 例在 NHS 无细胞 DNA 筛查实验室(SAFE 实验室)接受胎儿三体 NIPT 筛查的妊娠。
  • 采用筛查试验评价和周转时间分析,并用单因素及多因素 logistic 回归分析未出结果(低胎儿分数 <2%、极高胎儿分数 >40% 和处理失败)的显著预测因素。

主要发现

  • 平均周转时间为 4.0 天(95%CI 4.0-4.2 天)。
  • 21 三体灵敏度为 98.9%(95%CI 95.9-99.9%),13/18 三体灵敏度为 90.4%(95%CI 80.0-96.8%)。
  • 总体未出结果率为 32/8651(0.37%,95%CI 0.26-0.52%)。
  • 未出结果总体风险受孕周、双绒毛膜双胎妊娠、恶性肿瘤史及 13/18 三体妊娠影响,但不受孕妇体重或低分子肝素使用影响。

临床怎么用

  • 作者认为高通量 NIPT 可有效嵌入公共卫生 NHS 环境,周转时间和未出结果率在临床可接受范围内。
  • 作者认为孕周、孕妇体重、辅助生殖技术、低分子肝素使用及既往恶性肿瘤史不应构成不向女性提供 NIPT 选项的理由。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the effectiveness of secondary screening using non-invasive prenatal testing (NIPT) in a routine NHS setting including test performance, turn-around times (TATs) and no-call (failure to obtain result) rates. To examine the influence of maternal and fetal characteristics on test performance. DESIGN: Retrospective cohort. SETTING: London teaching hospital. SAMPLE: A total of 8651 pregnancies undergoing screening for fetal trisomy using NIPT provided by an NHS cell-free DNA screening laboratory - the SAFE laboratory. METHODS: Screening test evaluation and TATs. Univariate and multivariate logistic regression analysis to identify significant predictors of no-call results and reported by low fetal fraction (<2%), very high fetal fraction (>40%) and processing failure. MAIN OUTCOME MEASURES: Test performance, TATs and no-call rates, factors affecting no-call results. RESULTS: Average TAT was 4.0 days (95% CI 4.0-4.2 days). Test sensitivities for trisomies 21 and 13/18 were 98.9% (95% CI 95.9-99.9%) and 90.4% (95% CI 80.0-96.8%), respectively. The overall no-call rate was 32/8651 (0.37%, 95% CI 0.26-0.52%). The overall risk of a no-call result was influenced by gestational age, dichorionic twin pregnancy, history of malignancy and pregnancies affected by trisomy 13/18, but not by maternal weight or use of low-molecular-weight heparin. CONCLUSIONS: High-throughput NIPT can be effectively embedded into a public health NHS setting. TATs of 4 days and no-calls of <0.5% were well within clinically desirable tolerances. Gestational age, maternal weight, assisted reproductive techniques, use of low-molecular-weight heparin and past history of malignancy did not have major impacts on test no-call rates and should not constitute reasons for withholding the option of NIPT from women. TWEETABLE ABSTRACT: Turn-around times of 4 days, no-call (test failure) rates of 0.37% and highly accurate NIPT can be successfully embedded in the NHS.

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. Guy GP, Hargrave J, Dunn R, et al. Secondary non-invasive prenatal screening for fetal trisomy: an effectiveness study in a public health setting. BJOG. 2020. PMID: 32790109. doi:10.1111/1471-0528.16464

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。